person · Reporting owner

Earnhardt Lisa D

Disclosed activity across 3 companies

Tapewire entity: 14879
SEC CIK: 0001530893

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ABBOTT LABORATORIESABT · Entity 2314	EVP AND GROUP PRESIDENT	February 27, 2026	March 04, 2026
NEVRO CORPNVRO · Entity 12422	Director	May 21, 2018	May 23, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABBOTT LABORATORIES

Report date February 27, 2026 · Filed March 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common shares without par valueSEC Table I · non-derivative	Direct	90,407	Reported balance After 2026-02-27 transaction · row 1 1 source row Row 1 · 2026-02-27 · Tax withholding · Disposed 8,577 · Balance 90,407

NEVRO CORP

Report date May 21, 2018 · Filed May 23, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,303	Reported balance After 2018-05-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-05-21 · Grant · Acquired 3,785 · Balance 5,303 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2: Includes 3,785 RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer.

F2: Includes 3,785 RSUs.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Intersect ENT, Inc.

Report date July 24, 2019 · Filed July 26, 2019

Section 16 reporting ended · disclosed 2019-07-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-24 · Disposition to issuer · Disposed 44,625 · Balance 0 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-12-06	Direct	44,625	Reported balance After 2019-07-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-24 · Grant · Acquired 44,625 · Balance 44,625 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-07-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-12-06	Direct	150,000	Reported balance After 2019-07-24 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-07-24 · Grant · Acquired 150,000 · Balance 150,000 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-07-24 · Disposition to issuer · Disposed 196,875 · Balance 0 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-12-06	Direct	196,875	Reported balance After 2019-07-24 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-07-24 · Grant · Acquired 196,875 · Balance 196,875 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-07-24 · Disposition to issuer · Disposed 45,500 · Balance 0 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-12-06	Direct	45,500	Reported balance After 2019-07-24 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-07-24 · Grant · Acquired 45,500 · Balance 45,500 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-07-24 · Disposition to issuer · Disposed 48,333 · Balance 0 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-12-06	Direct	48,333	Reported balance After 2019-07-24 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-07-24 · Grant · Acquired 48,333 · Balance 48,333 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-10-22	Direct	0	Reported balance After 2019-07-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-24 · Disposition to issuer · Disposed 19,688 · Balance 0 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-12-06	Direct	19,688	Reported balance After 2019-07-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-07-24 · Grant · Acquired 19,688 · Balance 19,688 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
Common StockSEC Table I · non-derivative	Direct	353,183	Reported balance Holding disclosure · report date 2019-07-24 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 353,183
Common StockSEC Table I · non-derivative	IndirectSee footnote	26,182	Reported balance Holding disclosure · report date 2019-07-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 26,182 F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares.

F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.

F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.

F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.

F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.

F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.

F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2019 Filed Jun 12, 2019 21:08 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	17,431	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007549 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,431 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document
May 15, 2019 Filed May 17, 2019 16:06 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	9,500	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-19-002944 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 9,500 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option was January 1st, 2017. 1/8th of the shares subject to the option vested on July 1st, 2017 and 1/48th of the shares subject to the option vests monthly thereafter over 42 months. Read SEC document
May 15, 2019 Filed May 17, 2019 16:06 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	9,500	$25.59	$243,102.15	Disclosure SEC source: 0001562180-19-002944 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,983 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.31 to $25.92, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
May 15, 2019 Filed May 17, 2019 16:06 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	9,500	$13.05	$123,975.00	Disclosure SEC source: 0001562180-19-002944 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
April 15, 2019 Filed Apr 17, 2019 15:48 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	6,016	$0.00 Strike: $1.20	$0.00	Disclosure SEC source: 0001562180-19-002289 · primarydocument.xml · derivative · entry 6 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,333 Underlying: Common Stock · 6,016 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The vesting commencement date of the option is November 30, 2013. 1/48th of the shares subject to the option shall vest on December 30, 2013 and 1/48th of the shares subject to the option shall vest monthly thereafter over 47 months. Read SEC document
April 15, 2019 Filed Apr 17, 2019 15:48 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-19-002289 · primarydocument.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,500 Underlying: Common Stock · 7,500 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
April 15, 2019 Filed Apr 17, 2019 15:48 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	29,588	$28.43	$841,243.06	Disclosure SEC source: 0001562180-19-002289 · primarydocument.xml · nonDerivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,983 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 to $29.055, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
April 15, 2019 Filed Apr 17, 2019 15:48 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	6,016	$1.20	$7,219.20	Disclosure SEC source: 0001562180-19-002289 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
April 15, 2019 Filed Apr 17, 2019 15:48 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	7,500	$13.05	$97,875.00	Disclosure SEC source: 0001562180-19-002289 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
January 16, 2019 Filed Jan 18, 2019 17:38 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	157,500	$0.00 Strike: $28.58	$0.00	Disclosure SEC source: 0001562180-19-000374 · primarydocument.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2029-01-15 F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2019. 1/8th of the shares subject to the option shall vest on July 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
January 16, 2019 Filed Jan 18, 2019 17:38 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	33,800	$0.00	$0.00	Disclosure SEC source: 0001562180-19-000374 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,055 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing on January 1, 2019. F2 · balance_after: Includes 68,800 Restricted Stock Units. Read SEC document
January 01, 2019 Filed Jan 3, 2019 20:11 UTC	Intersect ENT, Inc. XENT · Entity 127294	Tax withholdingCommon Stock	10,428	$26.57	$277,045.89	Disclosure SEC source: 0001562180-19-000165 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,255 F1 · shares: Shares tendered in payment of the tax withholding obligation. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.43 to $26.86, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 35,000 Restricted Stock Units. Read SEC document
December 20, 2018 Filed Dec 26, 2018 12:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $1.20	$0.00	Disclosure SEC source: 0001562180-18-005094 · primarydocument.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,349 Underlying: Common Stock · 35,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The vesting commencement date of the option is November 30, 2013. 1/48th of the shares subject to the option shall vest monthly thereafter over 48 months. Read SEC document
December 20, 2018 Filed Dec 26, 2018 12:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	35,000	$1.20	$42,000.00	Disclosure SEC source: 0001562180-18-005094 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:16 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-005054 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:16 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$29.73	$594,504.00	Disclosure SEC source: 0001562180-18-005054 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 to $30.53, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:16 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-005054 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
November 15, 2018 Filed Nov 19, 2018 16:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-004613 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
November 15, 2018 Filed Nov 19, 2018 16:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$30.01	$600,296.00	Disclosure SEC source: 0001562180-18-004613 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $30.955, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
November 15, 2018 Filed Nov 19, 2018 16:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-004613 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
October 15, 2018 Filed Oct 17, 2018 18:54 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-004243 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
October 15, 2018 Filed Oct 17, 2018 18:54 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$29.63	$592,614.00	Disclosure SEC source: 0001562180-18-004243 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.37 to $30.34, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
October 15, 2018 Filed Oct 17, 2018 18:54 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-004243 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
September 17, 2018 Filed Sep 19, 2018 17:27 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-003986 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
September 17, 2018 Filed Sep 19, 2018 17:27 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$29.14	$582,862.00	Disclosure SEC source: 0001562180-18-003986 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $30.00, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
September 17, 2018 Filed Sep 19, 2018 17:27 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-003986 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
August 15, 2018 Filed Aug 17, 2018 19:05 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-003704 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
August 15, 2018 Filed Aug 17, 2018 19:05 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$26.51	$530,194.00	Disclosure SEC source: 0001562180-18-003704 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $27.05, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
August 15, 2018 Filed Aug 17, 2018 19:05 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-003704 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,500 Restricted Stock Units. Read SEC document
July 16, 2018 Filed Jul 18, 2018 18:09 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-003331 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
July 16, 2018 Filed Jul 18, 2018 18:09 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$33.08	$661,686.00	Disclosure SEC source: 0001562180-18-003331 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.55, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
July 16, 2018 Filed Jul 18, 2018 18:09 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-003331 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:22 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-003060 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:22 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	20,000	$36.79	$735,710.00	Disclosure SEC source: 0001562180-18-003060 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.55 to $37.05, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:22 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	5,000	$13.05	$65,250.00	Disclosure SEC source: 0001562180-18-003060 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2018 Filed May 23, 2018 19:16 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	3,785	$0.00	$0.00	Disclosure SEC source: 0001140361-18-025420 · doc1.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,303 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 3,785 RSUs. Read SEC document
May 15, 2018 Filed May 17, 2018 16:39 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-002535 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
May 15, 2018 Filed May 17, 2018 16:39 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	15,000	$39.22	$588,244.50	Disclosure SEC source: 0001562180-18-002535 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.35, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 15, 2018 Filed May 17, 2018 16:39 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	15,000	$13.05	$195,750.00	Disclosure SEC source: 0001562180-18-002535 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 16, 2018 Filed Apr 17, 2018 17:31 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-001903 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
April 16, 2018 Filed Apr 17, 2018 17:31 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	15,000	$39.59	$593,917.50	Disclosure SEC source: 0001562180-18-001903 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.35 to $39.80, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
April 16, 2018 Filed Apr 17, 2018 17:31 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	15,000	$13.05	$195,750.00	Disclosure SEC source: 0001562180-18-001903 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2018 Filed Mar 16, 2018 18:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-001657 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
March 15, 2018 Filed Mar 16, 2018 18:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	15,000	$38.32	$574,791.00	Disclosure SEC source: 0001562180-18-001657 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $38.55, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
March 15, 2018 Filed Mar 16, 2018 18:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	15,000	$13.05	$195,750.00	Disclosure SEC source: 0001562180-18-001657 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2018 Filed Feb 16, 2018 17:44 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-18-001054 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2017. 1/8th of the shares subject to the option shall vest on July 1, 2017 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document
February 15, 2018 Filed Feb 16, 2018 17:44 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	15,000	$36.40	$545,938.50	Disclosure SEC source: 0001562180-18-001054 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,683 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $36.95, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
February 15, 2018 Filed Feb 16, 2018 17:44 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	15,000	$13.05	$195,750.00	Disclosure SEC source: 0001562180-18-001054 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2018 Filed Jan 19, 2018 17:17 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	11,166	$33.47	$373,694.76	Disclosure SEC source: 0001562180-18-000368 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,683 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $33.80, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
January 17, 2018 Filed Jan 19, 2018 17:17 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	119,000	$0.00 Strike: $33.95	$0.00	Disclosure SEC source: 0001562180-18-000368 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2028-01-16 F5 · derivative.exercise_date: 1/8th of the shares subject to the option vest on July 1, 2018 and 1/48th of the total shares subject to the option vest monthly thereafter over 42 months. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.